ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 10:52 am EDT
Share
ShanXi C&Y Pharmaceutical Group Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 191.74 million compared to CNY 223.08 million a year ago. Revenue was CNY 191.74 million compared to CNY 223.08 million a year ago. Net loss was CNY 1.54 million compared to net income of CNY 1.02 million a year ago. Basic loss per share from continuing operations was CNY 0.0068 compared to basic earnings per share from continuing operations of CNY 0.0045 a year ago. Diluted loss per share from continuing operations was CNY 0.0068 compared to diluted earnings per share from continuing operations of CNY 0.0045 a year ago.
ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Companyâs main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.